Pfizer India on Thursday (October 19) said the regulatory landscape for drug approval in India is becoming more transparent and systematised, while also highlighting the increased speed with which pharmaceutical companies can introduce new drugs to the Indian market.

Share Market Live

NSE

Speaking at the PWC Pharma and Healthcare CEO Dialogues, Meenakshi Nevatia, the country president and managing director of Pfizer India, said, "A lot has changed in the positive direction in India. First, is about how quickly we are able to now bring drugs into the country and make new launches."

She said this acceleration in the drug launch process aligns with India's growing global connectivity, where both doctors and patients have access to information about the latest developments in the medical field worldwide.

Also Read: Glenmark Pharma shares gain on becoming first to launch Triple-drug FDC for Type 2 Diabetes

Further, Nevatia said the regulatory landscape for drug approval in India is becoming more transparent and systematised, "The regulatory process to bring drugs into the country is also getting much more transparent and systematised in a sense."

The Central Drugs Standard Control Organization (CDSCO) is actively exploring electronic submission processes, which will streamline and digitise the vast amount of data required for product approval, she pointed out.

This digital transformation is set to enhance the efficiency and transparency of bringing pharmaceutical products to the Indian market, Nevatia added.

(Edited by : Ajay Vaishnav)